Keyphrases
Psoriasis
100%
Fluticasone Propionate
100%
Ointment
100%
Corticosteroids
72%
Non-ablative
66%
Intertriginous Area
66%
Face Area
66%
Microdermabrasion
66%
Intertriginous
55%
Aluminum Oxide Crystals
41%
Photoaging
41%
Skin Atrophy
38%
Plaque
38%
Facial Area
36%
Short Contact Therapy
33%
Pulsed Dye Laser
33%
Ultrastructural Analysis
33%
Scleredema
33%
Infliximab
33%
Flashing Light
33%
Crohn's Disease
33%
Skin Rejuvenation
33%
Pyoderma Gangrenosum
33%
Anti-tumor Necrosis Factor Antibody
33%
Dermal Remodeling
33%
Clinical Evaluation
33%
Clinical Analysis
33%
Acne Vulgaris
33%
Photodamage
33%
Abrasion
33%
Atopic Dermatitis
33%
Tazarotene Gel
33%
Successful Treatment
33%
Histology
33%
Vehicle Control
33%
Treatment Efficacy
33%
Lentigo
33%
Eyelid Skin
33%
Diabetic Patients
33%
Acanthosis Nigricans
33%
Recurrence Rate
30%
Telangiectasia
30%
Once-daily
30%
Twice Daily
30%
Long-term Management
27%
Dosing Regimen
27%
Electron Microscopic
25%
Rhytids
25%
Skin Stiffness
22%
Sebum Content
22%
Medicine and Dentistry
Aluminum Oxide
44%
Photoaging
41%
Tazarotene
33%
Piperazine Sultosilate
33%
Scleredema
33%
Edema
33%
Acne Vulgaris
33%
Clinical Trial
33%
Sebum
33%
Reticular Dermis
33%
Rejuvenation
33%
Acneiform Eruption
33%
Lentigo
33%
Psoriasis
33%
Acanthosis Nigricans
33%
Back
33%
Adverse Event
22%
Diabetes Mellitus
20%
Ectasia
16%
Skin Temperature
16%
Skin Surface
16%
Mononuclear Cell
16%
Cellular Infiltration
16%
Blood Flow
16%
Facial Rejuvenation
16%
Patient Compliance
11%
Side Effect
11%
Skin Resurfacing
11%
Disease Severity
9%
Disease
9%
Retinoid
9%
Pigmentation
8%
Nd:YAG Laser
8%
Patient with Diabetes
6%
Pharmacology, Toxicology and Pharmaceutical Science
Fluticasone Propionate
100%
Psoriasis
66%
Skin Atrophy
38%
Acne Vulgaris
33%
Atopic Dermatitis
33%
Tumor Necrosis Factor
33%
Monoclonal Antibody
33%
Acne
33%
Pyoderma gangrenosum
33%
Crohn's Disease
33%
Tazarotene
33%
Telangiectasia
30%
Infliximab
27%
Skin Disease
22%
Recurrent Disease
19%
Recurrence Risk
19%
Adverse Event
14%
Fistula
11%
Disease Severity
9%
Cataract
8%
Drug Concentration
8%
Side Effect
8%
Glaucoma
8%
Disease
5%
Remission
5%
Enterocutaneous Fistula
5%
Rheumatoid Arthritis
5%
